#USA #New York #Securities Class Action #Faruqi & Faruqi #Zynex

Zynex Securities Class Action: Important Deadline Coming Up

As the deadline of April 21, 2026 approaches, Zynex, Inc. (OTCPK: ZYXIQ) investors are being urged to consider their legal options in relation to a federal securities class action. The law firm Faruqi & Faruqi, LLP specializes in securities law and has been investigating the circumstances surrounding Zynex's alleged misconduct that led to significant investor losses.

Background on Zynex

Zynex, a company known for supplying medical equipment, has been under scrutiny for potentially violating federal securities laws. Allegations suggest that Zynex misled investors about its revenue and operational integrity. The firm faced scrutiny over its business practices regarding the distribution of products and the filing of insurance claims.

The legal claim argues that Zynex and its executives made misleading statements that inflated their revenue and shielded the company's financial troubles. For instance, it has come to light that Zynex produced and shipped items, such as electrodes, beyond what was necessary, leading to artificially increased revenue figures. Furthermore, these practices have drawn criticism from insurance providers like Tricare, which have expressed concerns regarding payment practices.

Key Allegations Against Zynex

Credible claims have surfaced indicating that Zynex's aggressive sales strategies have prioritized revenue over compliance with industry regulations. Some of the specific allegations include:

• - The shipping of excess products that led to inflated revenue figures,
• - A fraudulent overbilling scheme that resulted in a lawsuit from insurance companies, including a damages claim exceeding $23 million,
• - Mismanagement and a lack of a solid internal control environment, which has placed the company in a precarious legal position.

In a recent financial report, Zynex revealed a significant dip in revenue attributed to delayed payments from insurers. Particularly alarming was the announcement that Zynex's primary customer, Tricare, had temporarily suspended payments for its claims, signaling potential long-term ramifications for the company’s revenue stream. After these revelations, Zynex's stock price took a substantial hit, dropping over 50% in a single day.

Why This Matters for Investors

Investors who have purchased or acquired Zynex securities between February 25, 2021, and December 15, 2025, need to be proactive in addressing their legal rights. The role of lead plaintiff is crucial in this class action suite, as it allows investors to guide and oversee litigation on behalf of the group.

Faruqi & Faruqi reminds investors that they have the option to either actively participate as lead plaintiffs or remain as passive class members. However, the decision to become a lead plaintiff could afford individuals greater influence over proceedings and recovery outcomes. The law firm has already successfully recouped hundreds of millions of dollars for investors in previous cases, underscoring their prowess in securities law.

How to Take Action

If you believe you are eligible to participate in this class action, it is essential to reach out to legal counsel. Faruqi & Faruqi’s Senior Partner, Josh Wilson, is available directly for consultations and can help clarify options for aggrieved investors. Interested parties can contact him at 877-247-4292 or 212-983-9330 (Ext. 1310).

Furthermore, any individuals with insider information regarding Zynex’s falsified activities are highly encouraged to come forward, as such information can significantly impact the case.

To stay updated, you can also visit Faruqi & Faruqi’s website for details on the Zynex class action. Given the complexities surrounding the case and the impending deadline, taking timely action is crucial for protecting your investment rights as a Zynex shareholder.